- Abstract:
-
BACKGROUND: Major depressive disorders (MDD) present a significant public health problem, in terms of burden for individual sufferers, their families and society as a whole. Recently, dualacting antidepressants, which block both serotonin (5-HT) and noradrenaline (NA) reuptake, have been developed with the hope of improving depression treatment outcomes. Duloxetine is a dual reuptake inhibitor of 5-HT and NA that has recently been licensed in the USA for the treatment of MDD. OBJECTIVE: This...
Expand abstract - Publication status:
- Published
- Journal:
- Current medical research and opinion
- Volume:
- 21
- Issue:
- 3
- Pages:
- 345-356
- Publication date:
- 2005-03-05
- DOI:
- EISSN:
-
1473-4877
- ISSN:
-
0300-7995
- URN:
-
uuid:48624e5a-0472-4e3a-b941-66846a7976aa
- Source identifiers:
-
139906
- Local pid:
- pubs:139906
- Copyright date:
- 2005
Journal article
Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
Actions
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record